SEC Form 4 · accession 0001209191-15-028985

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP & CFO

Period of report

Mar 23, 2015

Accepted (ET)

Mar 24, 2015 · 6:10 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F3	Mar 23, 2015	S	200	$122.44	D	123,976	D
Common Stock^F3,F4	Mar 23, 2015	S	200	$123.52	D	123,776	D
Common Stock^F3,F5	Mar 23, 2015	S	1,327	$124.87	D	122,449	D
Common Stock^F3,F6	Mar 23, 2015	S	2,815	$125.69	D	119,634	D
Common Stock^F3,F7	Mar 23, 2015	S	1,000	$126.65	D	118,634	D
Common Stock^F3,F8	Mar 23, 2015	S	500	$127.83	D	118,134	D
Common Stock	holding	—	—		—	5,306	I	401(k)

No Table II lines on this filing.

F1Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $122.44 (range $122.10 to $122.78).
F3Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $123.52 (range $123.10 to $123.93).
F5Open market sales reported on this line occurred at a weighted average price of $124.87 (range $124.28 to $125.24).
F6Open market sales reported on this line occurred at a weighted average price of $125.69 (range $125.28 to $126.24).
F7Open market sales reported on this line occurred at a weighted average price of $126.65 (range $126.29 to $127.07).
F8Open market sales reported on this line occurred at a weighted average price of $127.83 (range $127.39 to $128.19).